CHEMED CORP
For the period ended Sep 30, 2026. Filed Oct 29, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 29, 2026
CHE$544.49+1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Consolidated Statements of Cash Flows -
| CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||
|---|---|---|
| UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||
| (in thousands) | ||
| Nine Months Ended September 30, | ||
| 2026 | 2025 | |
| Cash Flows from Operating Activities | ||
| Net income | $205,653 | $188,487 |
| Adjustments to reconcile net income to net cash provided | ||
| by operating activities: | ||
| Depreciation and amortization | 51,260 | 48,511 |
| Stock option expense | 24,285 | 24,374 |
| Noncash long-term incentive compensation | 6,784 | 3,057 |
| Litigation settlements | 6,000 | 1,850 |
| Noncash directors' compensation | 1,191 | 1,123 |
| Benefit for deferred income taxes | (456) | (16,259) |
| Amortization of debt issuance costs | 255 | 241 |
| Changes in operating assets and liabilities: | ||
| Increase in accounts receivable | (71,304) | (44,403) |
| Increase in inventories | (205) | (45) |
| Increase in prepaid expenses | (11,528) | (8,603) |
| Increase in accounts payable and other current liabilities | 27,783 | 10,102 |
| Change in current income taxes | (7,685) | (2,162) |
| Net change in lease assets and liabilities | (667) | (576) |
| (Increase)/decrease in other assets | (9,356) | 42,048 |
| Increase in other liabilities | 6,772 | 6,355 |
| Other sources | 840 | 639 |
| Net cash provided by operating activities | 229,622 | 254,739 |
| Cash Flows from Investing Activities | ||
| Business combinations, net of cash acquired | (96,050) | (225) |
| Capital expenditures | (51,355) | (46,447) |
| Proceeds from sale of fixed assets | 488 | 3,751 |
| Other uses | (502) | (468) |
| Net cash used by investing activities | (147,419) | (43,389) |
| Cash Flows from Financing Activities | ||
| Proceeds from revolving line of credit | 843,280 | - |
| Payments on revolving line of credit | (607,280) | - |
| Purchases of treasury stock | (350,042) | (256,944) |
| Proceeds from exercise of stock options | 30,281 | 27,152 |
| Dividends paid | (25,234) | (23,196) |
| Change in cash overdrafts payable | 6,818 | 610 |
| Capital stock surrendered to pay taxes on stock-based compensation | (3,832) | (8,484) |
| Debt issuance costs | (1,349) | - |
| Other (uses)/sources | (933) | 914 |
| Net cash used by financing activities | (108,291) | (259,948) |
| Decrease in Cash and Cash Equivalents | (26,088) | (48,598) |
| Cash and cash equivalents at beginning of period | 74,515 | 178,350 |
| Cash and cash equivalents at end of period | $48,427 | $129,752 |
| See Accompanying Notes to Unaudited Consolidated Financial Statements. | ||
-5-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.